Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06625775CT.gov Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05358249CT.gov Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT04000529CT.gov Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | — | Terminated | — | — | — |
NCT02703571CT.gov Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ribociclib (this asset) | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | P1/2 | CC · 45 |
| Fluorouracilum | UNICANCER | P4 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Irinotecan | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Moviprep | Radboud University Medical Center | P4 | BB |
| Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Regorafenib | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Ribociclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | BB · 70 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BB · 69 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ribociclib in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ribociclib-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →